scholarly article | Q13442814 |
P819 | ADS bibcode | 2015PLoSO..1043393K |
P356 | DOI | 10.1371/JOURNAL.PONE.0143393 |
P932 | PMC publication ID | 4658115 |
P698 | PubMed publication ID | 26600308 |
P5875 | ResearchGate publication ID | 284713002 |
P50 | author | Kristi Alnek | Q115189670 |
Kalle Kisand | Q47869143 | ||
Raivo Uibo | Q20089700 | ||
P2093 | author name string | Liina Vahter | |
Katrin Gross-Paju | |||
Karin Kannel | |||
P2860 | cites work | Synthesis and release of B-lymphocyte stimulator from myeloid cells | Q73335981 |
Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity | Q81261843 | ||
BAFF is elevated in serum of patients with Wegener's granulomatosis | Q81389227 | ||
Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production | Q82993591 | ||
Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity | Q83366546 | ||
Pathogenesis of Sjögren's syndrome | Q84149203 | ||
Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse | Q84243273 | ||
Serum BAFF and APRIL might be associated with disease activity and kidney damage in patients with anti-glomerular basement membrane disease | Q85895154 | ||
Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome | Q43575541 | ||
Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases | Q45052751 | ||
A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses | Q45302161 | ||
Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases | Q45370998 | ||
Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome | Q46940748 | ||
Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis | Q47274470 | ||
Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. | Q47705615 | ||
Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis. | Q50944222 | ||
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. | Q51890331 | ||
Serum BAFF levels and skin mRNA expression in patients with Behçet's disease. | Q54506434 | ||
Relapses in multiple sclerosis are age- and time-dependent | Q59121723 | ||
Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid | Q59543689 | ||
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 | ||
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” | Q22252938 | ||
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 | ||
Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors | Q28254182 | ||
Body fluid biomarkers in multiple sclerosis | Q28303860 | ||
T cells, cytokines, and autoantigens in multiple sclerosis. | Q30680147 | ||
Immune thrombocytopenia and B-cell-activating factor/a proliferation-inducing ligand | Q33407661 | ||
Impact of multiple sclerosis relapses on progression diminishes with time | Q33898204 | ||
Treating multiple sclerosis with monoclonal antibodies: a 2013 update | Q34330211 | ||
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation | Q36161486 | ||
Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases | Q36703792 | ||
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges | Q36761844 | ||
Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils | Q37043905 | ||
Overlapping and distinct mechanisms of action of multiple sclerosis therapies. | Q37772310 | ||
Humoral autoimmunity in multiple sclerosis | Q37785326 | ||
Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis. | Q38069890 | ||
The BAFF/APRIL system in SLE pathogenesis. | Q38194895 | ||
Serum BAFF expression in patients with myasthenia gravis. | Q38500219 | ||
G-CSF-stimulated neutrophils are a prominent source of functional BLyS | Q41818295 | ||
Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy. | Q42503142 | ||
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial | Q42647640 | ||
Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population | Q42863405 | ||
Disease-modifying therapy in multiple sclerosis: update and clinical implications | Q43414869 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | e0143393 | |
P577 | publication date | 2015-11-23 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome | |
P478 | volume | 10 |
Q36005239 | Analysis of Associations of Human BAFF Gene Polymorphisms with Autoimmune Thyroid Diseases. |
Q104479846 | B cell depletion therapies in autoimmune disease: advances and mechanistic insights |
Q49874476 | B-Cell Therapies in Multiple Sclerosis |
Q38984981 | Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases |
Q90706043 | Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS? |
Q87984753 | Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies |
Q93006147 | High Pretransplant BAFF Levels and B-cell Subset Polarized towards a Memory Phenotype as Predictive Biomarkers for Antibody-Mediated Rejection |
Q39119839 | Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis |
Q40623713 | Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients |
Q48053281 | Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis. |
Q51668292 | Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon-β Therapy in Multiple Sclerosis Patients. |
Search more.